Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Tankyrase inhibitors (TNKSi) are gaining attention as potential anticancer agents.
• The Wnt/β-catenin signaling pathway is frequently dysregulated in various cancers.
• Targeting tankyrase offers a strategy to inhibit this oncogenic pathway.

Purpose of the Study:

• To review potent tankyrase inhibitors (TNKSi) with Wnt/β-catenin pathway disrupting activity.
• To classify TNKSi based on molecular interactions and their efficacy against Wnt cancer cell lines.
• To discuss structure-property relationships and preclinical data of promising TNKSi.

Main Methods:

• Literature review of tankyrase inhibitors.
• Classification of inhibitors based on drug design approaches and molecular interactions.
• Analysis of structure-property relationships and in vivo preclinical data.

Main Results:

• Overview of characterized TNKSi and their classification.
• Discussion of TNKSi effective against Wnt cancer cell lines.
• Presentation of structure-property relationships and preclinical efficacy in Wnt-driven cancer models.

Conclusions:

• Potent TNKSi targeting the Wnt/β-catenin pathway represent a promising therapeutic avenue for Wnt-driven cancers.
• Further research into TNKSi SPR and in vivo efficacy is crucial for clinical translation.
• Future directions include addressing current challenges and optimizing TNKSi development.